Found 2 bookmarks
Newest
Emerging viral threats combated by a potent new dual lipid kinase inhibitor
Emerging viral threats combated by a potent new dual lipid kinase inhibitor
“The researchers demonstrated selective dual inhibition of the lipid kinases PIP4K2C and PIKfyve by RMC-113 and target engagement by its related clickable analog. Advanced lipidomics revealed alteration of SARS-CoV-2-induced phosphoinositide signature by RMC-113 and linked its antiviral effect with functional PIP4K2C and PIKfyve inhibition. The researchers also discovered PIP4K2C's roles in SARS-CoV-2 entry, RNA replication, and assembly/egress, validating…”
#PIKfyve and PIP5K1C inhibitor#antiviral#treatment#research#PIKfyve and PIP4K2C inhibitor
·flip.it·
Emerging viral threats combated by a potent new dual lipid kinase inhibitor
Thread by @DrEricDing on Thread Reader App
Thread by @DrEricDing on Thread Reader App
“I'm shocked a lot of doctors don't know about this newer flu antiviral drug called Baloxavir (XOFLUZA)... that shortens your flu illness by 33%, and reduces your viral load by day 2, versus what a placebo takes 5-6 days to achieve. Baloxavir also seems superior to TAMIFLU (oseltamivir) for smashing your viral load on 2 day, achieving what takes Tamiflu 3-4 days. CDC even lists Baloxavir on their website as one of the top 4 drugs that it tracks whether it works against new flu strains (it works)”
#Influenza#Discussion#XOfluza#antiviral#treatment
·threadreaderapp.com·
Thread by @DrEricDing on Thread Reader App